MedTrace Logo

A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

NCT06885385 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-24

No results posted yet for this study

Summary

This study is an open label, multicenter Phase II clinical trial aimed at evaluating the safety and efficacy of JS207 with or without JS015 in combination with chemotherapy (XELOX) as a first-line treatment for advanced colorectal cancer with MSS/pMMR. The study was divided into two cohorts: Cohort 1 was JS207 combined with XELOX, and Cohort 2 was JS207 combined with JS015 and XELOX.

Conditions

  • Advanced Colorectal Cancer

Interventions

BIOLOGICAL

JS207

JS207 will be administered every 3 weeks for a treatment cycle of 21 days

BIOLOGICAL

JS015

JS015 will be administered every 3 weeks for a treatment cycle of 21 days

DRUG

Capecitabine

Capecitabine of 1000mg/m2 will be administered orally twice daily from day 1 to 14 every 21 day cycle

DRUG

Oxaliplatin

Oxaliplatin of 130mg/m2 will be administered intravenously (IV) on day 1 every 21 day cycle

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-23
Primary Completion
2026-11-27
Completion
2027-02-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06885385 on ClinicalTrials.gov